Latest Conference Coverage


Exon-Skipping Therapy Golodirsen Prolongs Ambulation in DMD, Long-Term Study Shows

Exon-Skipping Therapy Golodirsen Prolongs Ambulation in DMD, Long-Term Study Shows

March 4th 2024

Median time to loss of ambulation for golodirsen-treated patients was 1968 days vs 1092 days for external control patients.


David Lynch, MD, PhD, neurologist and director of the Friedreich's Ataxia Program at Children's Hospital of Philadelphia

Vatiquinone Treatment Shows Benefit Across End Points for Friedreich Ataxia in Phase 3 MOVE-FA Trial

March 4th 2024

A new analysis of phase 3 MOVE-FA trial presented at MDA 2024 revealed promising outcomes for vatiquinone, an oral 15-lipoxygenase inhibitor, in patients with Friedreich ataxia.


Stephen Krieger, MD; Enrique Alvarez, MD, PhD

Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments: Stephen Krieger, MD; Enrique Alvarez, MD, PhD

March 4th 2024

The associate professor of neurology at Icahn School of Medicine at Mount Sinai and associate professor of neurology at University of Colorado School of Medicine talked about the potential of redefining relapses in the landscape of clinical trials for multiple sclerosis. [WATCH TIME: 3 minutes]


SRP-9001 Improves Duchenne Muscular Dystrophy Disease Trajectory Despite Failing to Meet Primary End Point in Phase 3 EMBARK Trial

SRP-9001 Improves Duchenne Muscular Dystrophy Disease Trajectory Despite Failing to Meet Primary End Point in Phase 3 EMBARK Trial

March 4th 2024

Over a 52-week treatment period, treatment with SRP-9001 resulted in improvements in secondary outcomes of time to rise, micro-dystrophin expression, and 10-meter walk/run.


Yinan Zhang, MD

The Intricate Relationship Between Biological Aging and Multiple Sclerosis: Yinan Zhang, MD

March 4th 2024

The assistant professor of neurology at The Ohio State University Wexner Medical Center talked about results from an ongoing study assessing biological aging in patients with multiple sclerosis using epigenetic clocks and p16INK4a. [WATCH TIME: 6 minutes]


Duchenne Therapy Eteplirsen Safe in Infants as Young as 6 Months, Study Shows

Duchenne Therapy Eteplirsen Safe in Infants as Young as 6 Months, Study Shows

March 4th 2024

Patients with Duchenne muscular dystrophy between ages of 6 and 24 months old demonstrated a similar safety profile on eteplirsen than those between 24 and 48 months of age.


Interim Real-World Data From Phase 4 EVOLVE Study Demonstrate Sustained Treatment Effect of Eteplirsen

Interim Real-World Data From Phase 4 EVOLVE Study Demonstrate Sustained Treatment Effect of Eteplirsen

March 3rd 2024

In a real-world study, eterplirsen was safe for patients with Duchenne muscular dystrophy, with sustained or improved status in function.


Tadalafil Improves Microvascular Function in Duchenne Leg Muscles, Study Suggests

Tadalafil Improves Microvascular Function in Duchenne Leg Muscles, Study Suggests

March 3rd 2024

Tadalafil shows potential in addressing microvascular impairment in Duchenne muscular dystrophy, with post-contractile MRI as a screening tool.


Safety Profile of Fenebrutinib in MS Similar to Other Autoimmune Conditions

Safety Profile of Fenebrutinib in MS Similar to Other Autoimmune Conditions

March 3rd 2024

Phase 2 study analysis of Roche's fenebrutinib reveals similar safety profiles across multiple autoimmune indications, including relapsing multiple sclerosis.


Reaction to 2024 MDA Legacy Award: Jeff Chamberlain, PhD

Reaction to 2024 MDA Legacy Award: Jeff Chamberlain, PhD

March 3rd 2024

Jeff Chamberlain, PhD, a leading professor in gene therapy focused on Duchenne muscular dystrophy, shared his reaction to being named the recipient of the 2024 MDA Legacy Award, as well as the state of the DMD field currently.


Robert J. Fox, MD, staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic

Analyzing Phase 2 CALLIPER Trial of IMU-838 for Progressive MS: Robert J. Fox, MD

March 3rd 2024

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from an interim analysis of the phase 2 CALLIPER trial assessing vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 4 minutes]


Matthew R. Brier, MD, PhD, neurology chief resident at Washington University in St. Louis

Increased Aerobic Glycolysis in Normal Appearing White Matter Revealed as Metabolic Abnormality in Multiple Sclerosis

March 3rd 2024

A recent study presented at the 2024 ACTRIMS Forum suggests that increased aerobic glycolysis in normal appearing white matter may be an early feature of multiple sclerosis.


Joanna Kocot, PhD, Rocky Beth fellow at National Institutes of Health

Clemastine Arm of TRAP-MS Trial Halted Following Increased Disability Accumulation in Progressive Multiple Sclerosis

March 2nd 2024

New data from the TRAP-MS trial showed clemastine fumarate's association with increased disability accumulation in cases of non-lesional multiple sclerosis.


Fumie Hayashi, MD, PhD, a postdoctoral fellow in the department of Neurology at University of California, San Francisco

Study Reveals Expanded CD8+ T Cell Clonotypes in Cerebrospinal Fluid in Patients With Multiple Sclerosis

March 2nd 2024

A recent study presented the 2024 ACTRIMS Forum showed that a subset of CD8+ T cells preferentially expanded in the cerebrospinal fluid of patients with multiple sclerosis.


Theodore H. Schwartz, MD, professor of neurological surgery at Weill Cornell Medicine

Paramagnetic Rim Lesions Predicts Future Cognitive Decline in Multiple Sclerosis

March 2nd 2024

A recent study presented at the 2024 ACTRIMS Forum revealed the association between paramagnetic rim lesions and subsequent cognitive decline in patients with multiple sclerosis.


Yinan Zhang, MD, assistant professor of neurology at The Ohio State University Wexner Medical Center

Epigenetic Age Acceleration Shows Association With Secondary Progressive Multiple Sclerosis

March 2nd 2024

New findings from a study presented at the 2024 ACTRIMS Forum revealed an increase in epigenetic age acceleration among a subgroup of patients with multiple sclerosis.


Individual and Group Level Cognitive Benefits of Cladribine Displayed in MAGNIFY-MS Study

Individual and Group Level Cognitive Benefits of Cladribine Displayed in MAGNIFY-MS Study

March 2nd 2024

Using a 4-point score change on Symbol Digits Modalities Test, more than 80% of patients had either sustained improvement or no sustained change after 2 years of treatment with cladribine.


Jeffery Cohen, MD

Ozanimod's Consistent Efficacy in Long-Term Treatment for Multiple Sclerosis: Jeffery Cohen, MD

March 1st 2024

The director of Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research talked about recent findings on long-term impact of ozanimod in patients with relapsing-remitting multiple sclerosis presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]


 Marjan Gharagozloo, PhD, assistant professor of neurology at Johns Hopkins Medicine

Preclinical Data Shows NLRX1 Protects Against Neurodegeneration in Multiple Sclerosis

March 1st 2024

A new study showed that NLRX1, a mitochondrial innate immune sensor, may serve as a promising therapeutic target to prevent inflammatory neurodegeneration in multiple sclerosis.


Challenges for the Neuromuscular Community Entering Treatment Era: Barry Byrne, MD, PhD

Challenges for the Neuromuscular Community Entering Treatment Era: Barry Byrne, MD, PhD

March 1st 2024

The chief medical advisor at the Muscular Dystrophy Association provided perspective on the upcoming meeting and the conversations surrounding new therapeutics for diseases that once had little to nothing. [WATCH TIME: 4 minutes]


Lars Alfredsson, PhD, professor in the department of clinical neuroscience at Karolinska Institutet in Stockholm, Sweden,

Obesity Accelerates Disease Progression in Patients With Multiple Sclerosis

March 1st 2024

A recent study presented at 2024 ACTRIMS Forum showed that body mass index may influence disease progression in patients with multiple sclerosis.


Neurofilament Light Levels Predict Future MS Disease Activity Regardless of Race or Ethnicity

Neurofilament Light Levels Predict Future MS Disease Activity Regardless of Race or Ethnicity

February 29th 2024

These data, presented at 2024 ACTRIMS Forum, highlight the impacts neurofilament light has on patients with multiple sclerosis irrespective of race or ethnicity.


Bruce Cree, MD, PhD, MAS, professor of clinical neurology at University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center

Phase 3 DAYBREAK Trial Highlights Long-Term Efficacy of Ozanimod for Relapsing Multiple Sclerosis

February 29th 2024

Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.


Ashkan Shoamanesh, MD

Secondary Analyses of ANNEXA-I Trial Assessing Andexanet Alfa in Intracranial Hemorrhage: Ashkan Shoamanesh, MD

February 28th 2024

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]


Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MS

Efficacy of Adjunctive Therapies for Acute Ischemic Stroke Based on Phase 3 MOST Trial: Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MS

February 26th 2024

The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]


David Z. Rose, MD

Cost-Effective Detection of Poststroke Atrial Fibrillation Identified in STROKE-AF Trial: David Z. Rose, MD

February 25th 2024

The professor of neurology at University of South Florida talked about the cost-effectiveness of insertable cardiac monitors to detect new atrial fibrillation in patients with large-artery or small-vessel disease stroke. [WATCH TIME: 4 minutes]


Future Role of Neurofilament Light in ALS Drug Development, Clinical Trials: Rita Sattler, PhD, MSc

Future Role of Neurofilament Light in ALS Drug Development, Clinical Trials: Rita Sattler, PhD, MSc

February 23rd 2024

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided perspective on the approval of tofersen (Qalsody; Biogen) for patients with ALS and the ways neurofilament light will be used going forward. [WATCH TIME: 3 minutes]


Shadi Yaghi, MD, associate professor of neurology at Brown University

Antiplatelets Versus Anticoagulation For the Treatment of Cervical Artery Dissection: Shadi Yaghi, MD

February 22nd 2024

The associate professor of neurology at Brown University talked about findings from an observational study investigating treatment options antiplatelets and anticoagulation for cervical artery dissection. [WATCH TIME: 8 minutes]


Lessons Learned From Cleveland Clinic’s Mobile Stroke Unit: Blake Buletko, MD

Lessons Learned From Cleveland Clinic’s Mobile Stroke Unit: Blake Buletko, MD

February 22nd 2024

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on the biggest learning experiences over the past decade for Cleveland Clinic’s mobile stroke unit. [WATCH TIME: 4 minutes]

© 2024 MJH Life Sciences

All rights reserved.